CY1125293T1 - Ενωσεις 1η-ινδαζολο-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης του γλυκογονου - Google Patents

Ενωσεις 1η-ινδαζολο-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης του γλυκογονου

Info

Publication number
CY1125293T1
CY1125293T1 CY20221100366T CY221100366T CY1125293T1 CY 1125293 T1 CY1125293 T1 CY 1125293T1 CY 20221100366 T CY20221100366 T CY 20221100366T CY 221100366 T CY221100366 T CY 221100366T CY 1125293 T1 CY1125293 T1 CY 1125293T1
Authority
CY
Cyprus
Prior art keywords
disorders
indazole
inhibitors
beta
kinase
Prior art date
Application number
CY20221100366T
Other languages
Greek (el)
English (en)
Inventor
Guido Furlotti
Claudia CAVARISCHIA
Rosa BUONFIGLIO
Rosella Ombrato
Tommaso Iacoangeli
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of CY1125293T1 publication Critical patent/CY1125293T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20221100366T 2018-05-07 2022-05-26 Ενωσεις 1η-ινδαζολο-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης του γλυκογονου CY1125293T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18171084 2018-05-07

Publications (1)

Publication Number Publication Date
CY1125293T1 true CY1125293T1 (el) 2025-03-28

Family

ID=62134122

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100366T CY1125293T1 (el) 2018-05-07 2022-05-26 Ενωσεις 1η-ινδαζολο-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης του γλυκογονου

Country Status (28)

Country Link
US (1) US11472795B2 (https=)
EP (1) EP3790873B1 (https=)
JP (1) JP7411574B2 (https=)
KR (1) KR102778690B1 (https=)
CN (1) CN112135821B (https=)
AU (1) AU2019265606B2 (https=)
BR (1) BR112020021922A2 (https=)
CA (1) CA3094896A1 (https=)
CY (1) CY1125293T1 (https=)
DK (1) DK3790873T3 (https=)
EA (1) EA202092422A1 (https=)
ES (1) ES2913975T3 (https=)
GE (2) GEP20227437B (https=)
HR (1) HRP20220664T1 (https=)
HU (1) HUE058894T2 (https=)
IL (1) IL278330B2 (https=)
LT (1) LT3790873T (https=)
MA (1) MA52557A (https=)
MD (1) MD3790873T2 (https=)
MX (1) MX2020011882A (https=)
PL (1) PL3790873T3 (https=)
PT (1) PT3790873T (https=)
RS (1) RS63255B1 (https=)
SG (1) SG11202009230WA (https=)
SI (1) SI3790873T1 (https=)
SM (1) SMT202200227T1 (https=)
UA (1) UA128089C2 (https=)
WO (1) WO2019215075A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506257A (ja) * 2019-12-16 2023-02-15 コリア リサーチ インスティチュート オブ ケミカル テクノロジー 新規なインダゾール誘導体及びその用途
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
WO2022125377A1 (en) * 2020-12-08 2022-06-16 Disarm Therapeutics, Inc. Benzopyrazole inhibitors of sarm1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257545A (en) 1992-11-05 1997-01-29 Smithkline Beecham Plc Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3473099A1 (en) * 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
CA2860250C (en) * 2012-02-21 2020-11-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
RS54539B1 (sr) 2012-02-21 2016-06-30 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze
MX2016012208A (es) * 2014-03-20 2017-01-26 Samumed Llc Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas.
AU2019224075A1 (en) * 2018-02-23 2020-09-10 Samumed, Llc 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof

Also Published As

Publication number Publication date
MA52557A (fr) 2021-03-17
WO2019215075A1 (en) 2019-11-14
UA128089C2 (uk) 2024-04-03
IL278330A (https=) 2020-12-31
EP3790873A1 (en) 2021-03-17
JP7411574B2 (ja) 2024-01-11
JP2021523134A (ja) 2021-09-02
EP3790873B1 (en) 2022-04-27
CN112135821A (zh) 2020-12-25
IL278330B2 (en) 2024-06-01
KR102778690B1 (ko) 2025-03-12
US20210053956A1 (en) 2021-02-25
DK3790873T3 (da) 2022-05-23
SG11202009230WA (en) 2020-11-27
MX2020011882A (es) 2021-01-20
HRP20220664T1 (hr) 2022-06-24
MD3790873T2 (ro) 2022-07-31
SMT202200227T1 (it) 2022-07-21
EA202092422A1 (ru) 2021-02-12
BR112020021922A2 (pt) 2021-01-26
GEAP202215506A (en) 2022-07-11
IL278330B1 (en) 2024-02-01
KR20210005863A (ko) 2021-01-15
AU2019265606A1 (en) 2020-10-15
ES2913975T3 (es) 2022-06-07
AU2019265606B2 (en) 2023-10-12
CA3094896A1 (en) 2019-11-14
SI3790873T1 (sl) 2022-07-29
CN112135821B (zh) 2024-05-31
LT3790873T (lt) 2022-06-10
US11472795B2 (en) 2022-10-18
HUE058894T2 (hu) 2022-09-28
RS63255B1 (sr) 2022-06-30
PT3790873T (pt) 2022-05-11
PL3790873T3 (pl) 2022-06-27
GEP20227437B (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CY1125293T1 (el) Ενωσεις 1η-ινδαζολο-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης του γλυκογονου
CY1117469T1 (el) Ενωσεις 1η-ινδαζολης-3-καρβοξαμιδης ως αναστολεις της κινασης 3 βητα της συνθασης γλυκογονου
CY1125786T1 (el) Οι διαρυλικοι μακροκυκλοι ως ρυθμιστες πρωτεϊνικων κινασων
CY1117467T1 (el) Χρηση των ενωσεων 1η-ινδαζολης-3- καρβοξαμιδης ως αναστολεις της κινασης 3 β της συνθασης γλυκογονου
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
MX2023009652A (es) Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras.
CY1123231T1 (el) Ενωσεις τετραϋδροπυριμιδοδιαζεπινης και τετραϋδροπυριδοδιαζεπινης για θεραπεια πονου και καταστασεων σχετικων με τον πονο
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
SA521430753B1 (ar) Kcnt1 مثبطات وطرق استخدامها
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
CY1125169T1 (el) ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA202090871A1 (ru) Ингибирование убиквитин-специфической пептидазы 30
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
MX2020003961A (es) Uso de inhibidores de p38 para reducir la expresion de dux4.
JOP20210318B1 (ar) مثبطات جزيئية صغيرة لكيناز تحفيز NF-κB
NZ758291A (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
PH12019501534A1 (en) Csf1r-based chimeric proteins
EA202090414A1 (ru) Соединения и их применение
CY1125138T1 (el) Ενωσεις πυριδυλπυριδονης
MX2022003236A (es) Bencimidazol carboxamidas sustituidas y su uso en el tratamiento de trastornos medicos.
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου